GBS Inc. (GBS): Price and Financial Metrics
GBS Price/Volume Stats
| Current price | $0.47 | 52-week high | $2.89 |
| Prev. close | $0.47 | 52-week low | $0.36 |
| Day low | $0.45 | Volume | 11,000 |
| Day high | $0.49 | Avg. volume | 955,325 |
| 50-day MA | $0.52 | Dividend yield | N/A |
| 200-day MA | $0.71 | Market Cap | 7.05M |
GBS Stock Price Chart Interactive Chart >
GBS Inc. (GBS) Company Bio
GBS Inc. operates as a biosensor diagnostic technology company. Its principal product is Saliva Glucose Biosensor, a saliva glucose monitoring system for diabetes management. The company also focuses on developing other diagnostic tests in the areas of biochemistry, tumor markers, immunology, hormones, and other biomarkers. It operates in Mainland China, Hong Kong, Vietnam, and Bangladesh. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was founded in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Latest GBS News From Around the Web
Below are the latest news stories about GBS INC that investors may wish to consider to help them evaluate GBS as an investment opportunity.
Intelligent Bio Solutions Inc. Announces Leading U.K. Container Haulier Switching to Fingerprint Drug Screening System for In-house TestingGoldstar Transport to Remove Urine Testing for Sweat Based TechnologyNEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the "Company”), a life sciences company delivering intelligent, non-invasive, real-time testing solutions, today announced that Goldstar Transport, the UK’s market-leading container haulier, has switched out urine tests for fingerprint drug testing. Goldstar employs approximately 600 LGV drivers, 170 office staff and 40 container lifter s |
GBS Inc. Initiates Company Name Change to Intelligent Bio Solutions Inc. (IBSS) and Announces Key Executive Appointments- Name change to more closely reflect firm’s expanding portfolio of intelligent, efficient, convenient and practical noninvasive and drug testing technologies and products - - Harry Simeonidis appointed as Chief Executive Officer - - David Jenkins and Jason Isenberg appointed to Board of Directors - NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), now Intelligent Bio Solutions Inc. (Nasdaq: IBSS) (the "Company”), a life sciences company developing non-invasive, real-time diagn |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time for another overview of the biggest pre-market stock movers for Wednesday as we cover the news behind share movement this morning! |
GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening TechnologyThe transaction further solidifies GBS’ leadership in non-invasive, real-time diagnostic testing with an expanded portfolio and geographical reachGBS’ global footprint includes operations in Australia, United Kingdom and the US NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, today announced it has acquired Intelligent Fingerprinti |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning! |
GBS Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | 11.90% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2022 | 0.00% |
| 2021 | -80.61% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...